Medicament composition for treating respiratory disease

A composition and respiratory technology, applied in the field of salt compositions containing glucocorticoids and leukotriene antagonists, can solve problems such as reducing adverse reactions and the like

Inactive Publication Date: 2009-01-21
TIANJIN PHARMA GROUP CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] In order to solve the above-mentioned technical problems and reduce the dosage, the present invention provides a composition for treating respiratory diseases, which is a composition of a leukotriene antagonist and a glucocorticoid. The composition directly acts on the respiratory tract without oral administration. Reduce the dosage, and the corresponding adverse reactions will be relatively reduced, which can overcome the shortcomings of the prior art, avoid the potential danger of the inhaled glucocorticoid / long-acting β2 receptor agonist in the prior art, and at the same time have the advantages of convenience in use and ease of administration. The advantage of less

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition for treating respiratory disease
  • Medicament composition for treating respiratory disease
  • Medicament composition for treating respiratory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Montelukast 20g

[0042] Budesonide 10g

[0043] Ethanol 750g

[0044] Propylene glycol 150g

[0045] Dichlorodifluoromethane 1500g

[0046] Preparation process: Add the prescribed amount of montelukast and budesonide into ethanol and propylene glycol that are evenly stirred, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal the dose valve The system is respectively pressurized and injected with dichlorodifluoromethane to obtain the product. Theoretical filling is 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 400 μg of montelukast and 200 μg of budesonide.

Embodiment 2

[0048] Montelukast Sodium 12.5g

[0049] Ciclesonide 3.5g

[0050] Ethanol 200g

[0051] Glycerol 19.5g

[0052] HFA227 750g

[0053] HFA134a 750g

[0054] Vitamin C 7.5g

[0055] Preparation process: add the prescribed amount of montelukast and ciclesonide into the well-stirred vitamin C, ethanol and glycerol, stir, heat in a warm water bath to dissolve the raw materials, filter through a sand core funnel, and pour in doses Packing and sealing the dosage valve system, respectively repressurizing HFA134a and HFA227 to obtain, theoretically canning 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 250 μg of montelukast sodium and 70 μg of ciclesonide.

Embodiment 3

[0057] Montelukast 5g

[0058] Fluticasone Propionate 10g

[0059] Ethanol 750g

[0060] Glycerin 150g

[0061] Dichlorotetrafluoroethane 1500g

[0062] Sodium metabisulfite 7.5g

[0063] Preparation process: Add the prescribed amount of montelukast and fluticasone propionate into the well-stirred sodium metabisulfite, ethanol and glycerin, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, The dose valve system is sealed, and the dichlorotetrafluoroethane is respectively pressurized to obtain the product. The theoretical canning is 1000 bottles, and the filling yield is over 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle contains 50 presses, each press contains 100 μg of montelukast and 200 μg of fluticasone propionate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for the treatment of respiratory diseases, in particular asthma, rhinitis or COPD and especially asthma. Particularly, the composition contains glucocorticoid and leukotriene antagonist, especially Ciclesonide, Montelukast and salts usable for treatment. The pharmaceutical composition can be prepared to compound respirable powder and aerosol, irrespirable powder and aerosol and pressurized spray.

Description

technical field [0001] The invention provides a pharmaceutical composition for treating respiratory diseases, especially asthma, rhinitis or chronic obstructive pulmonary disease (COPD), especially asthma, especially containing glucocorticoid and leukotriene antagonist, especially containing ciclesonide Compositions with montelukast and therapeutically useful salts. Background technique [0002] Asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway responsiveness. Airway obstruction is caused by two factors: increased secretions caused by bronchial mucosal inflammation, mucosal edema, and smooth muscle spasm stimulated by inflammation; while asthma Increased airway reactivity is also a result of damage to the bronchial epithelium due to airway inflammation. It is recognized that only by controlling the inflammation of the airway mucosa can the ultimate goal of reducing airway hyperresponsiveness and relieving asthma symp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/58A61K31/573A61K31/56A61K9/12A61P11/02A61P11/06A61P11/00A61K31/47A61K31/41A61K31/404
Inventor 李静程振国陈松
Owner TIANJIN PHARMA GROUP CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap